glp-1 news today november 2025 Pipeline Update: August - Prime Therapeutics GLP-1 trends 2025: real-world data,

Understanding how they actually differ matters, because matching the wrong peptide to the wrong goal produces disappointing results or unnecessary side effects

Ready to explore peptide therapy for recovery and performance

Powerful stuff, really

In addition, if any of our product candidates receive marketing approval, the FDA could require us to include a boxed warning in our label or adopt a risk evaluation and mitigation strategy (REMS), to ensure that the benefits outweigh its risks, which may include, among other things, a medication guide outlining the risks of the drug for distribution to patients and a communication plan to health care practitioners